✦ LIBER ✦

Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer

✍ Scribed by Brugger, W.; Triller, N.; Blasinska-Morawiec, M.; Curescu, S.; Sakalauskas, R.; Manikhas, G. M.; Mazieres, J.; Whittom, R.; Ward, C.; Mayne, K.; Trunzer, K.; Cappuzzo, F.

Book ID: 121346180
Publisher: American Society of Clinical Oncology
Year: 2011
Tongue: English
Weight: 200 KB
Volume: 29
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2010.31.8162

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

22LBA Overall survival analyses from the

22LBA Overall survival analyses from the SATURN phase III placebo-controlled study of erlotinib as first-line maintenance therapy in advanced non-small-cell lung cancer (NSCLC)

✍ F. Cappuzzo; B. Coudert; R. Wierzbicki; K. Park; F. Custers; G.A. Curbera; G. Gi 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Randomized, Placebo-Controlled, Phase II

Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer

✍ Mok, T. S.K.; Wu, Y.-L.; Yu, C.-J.; Zhou, C.; Chen, Y.-M.; Zhang, L.; Ignacio, J 📂 Article 📅 2009 🏛 American Society of Clinical Oncology 🌐 English ⚖ 151 KB

Randomized, Double-Blind, Placebo-Contro

Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer

✍ Spigel, D. R.; Burris, H. A.; Greco, F. A.; Shipley, D. L.; Friedman, E. K.; Wat 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 161 KB

Biomarker Analyses from a Placebo-Contro

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib Onartuzumab in Advanced Non-Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

✍ Koeppen, H.; Yu, W.; Zha, J.; Pandita, A.; Penuel, E.; Rangell, L.; Raja, R.; Mo 📂 Article 📅 2014 🏛 American Association for Cancer Research 🌐 English ⚖ 677 KB

Efficacy and safety of maintenance erlot

Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: A subanalysis of the phase III, randomized SATURN study

✍ Wu, Yi-Long; Kim, Joo-Hang; Park, Keunchil; Zaatar, Adel; Klingelschmitt, Gaëlle 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 247 KB

PCN97 COST EFFECTIVENESS OF ERLOTINIB TR

PCN97 COST EFFECTIVENESS OF ERLOTINIB TREATMENT GIVEN BY A CLINICALLY BASED APPROACH AND AN EGFR/KRAS TESTING-GUIDED APPROACH ADVANCED IN NON SMALL-CELL LUNG CANCER: A PROSPECTIVE MULTICENTRIC FRENCH STUDY (ERMETIC)

✍ I Borget; J Cadranel; JP Pignon; G Danton; B Coudert; E Dansin; S Friard; C Dani 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB